{"id":25408,"date":"2012-03-09T19:03:19","date_gmt":"2012-03-09T23:33:19","guid":{"rendered":"http:\/\/piel-l.org\/blog\/?p=25408"},"modified":"2012-03-09T22:40:13","modified_gmt":"2012-03-10T03:10:13","slug":"skin-cancer-after-pancreas-transplantation","status":"publish","type":"post","link":"https:\/\/piel-l.org\/blog\/25408","title":{"rendered":"Skin cancer after pancreas transplantation"},"content":{"rendered":"<p>J Am Acad Dermatol. 2012 Feb 14. <\/p>\n<p>Spanogle JP, Kudva YC, Dierkhising RA, Kremers WK, Roenigk RK, Brewer JD, Prieto M, Otley CC.<\/p>\n<p><!--more--><\/p>\n<p>&nbsp;<\/p>\n<p>Source<\/p>\n<p>Department of Dermatology, Mayo Clinic, Rochester, Minnesota.<\/p>\n<p>Abstract<\/p>\n<p>BACKGROUND: Skin cancer in patients who have undergone pancreas transplantation (PT) has not been extensively characterized.<\/p>\n<p>OBJECTIVE: We sought to describe the incidence, tumor burden, and risk factors for skin cancer in PT recipients at Mayo Clinic from 1998 through 2006.<\/p>\n<p>METHODS: A retrospective study was performed by analyzing outcomes among a cohort of pancreas allograft recipients at Mayo Clinic between 1998 and 2006.<\/p>\n<p>\u00a0RESULTS: Among 216 allogeneic PT recipients at 2, 5, and 10 years posttransplantation, the cumulative incidence of any skin cancer was 4.7%, 12.7%, and 19.6%; the cumulative incidence of squamous cell carcinoma was 2.8%, 10.3%, and 16.7%; and the cumulative incidence of basal cell carcinoma was 2.4%, 7.8%, and 17.4%, respectively. The cumulative incidence of a second squamous cell carcinoma developing was 56% at 2 years; the cumulative incidence of a second basal cell carcinoma developing was 36% at 2 years. Of the risk factors examined, only age and having a skin cancer before transplantation were predictive of skin cancer development.<\/p>\n<p>LIMITATIONS: This was a retrospective study. Results from a large tertiary center may not be generalizable.<\/p>\n<p>CONCLUSIONS: Nonmelanoma skin cancers commonly occur in recipients of PT, and those patients who have a history of nonmelanoma skin cancer have a very high likelihood of further skin cancer development<\/p>\n","protected":false},"excerpt":{"rendered":"<p>J Am Acad Dermatol. 2012 Feb 14. Spanogle JP, Kudva YC, Dierkhising RA, Kremers WK, Roenigk RK, Brewer JD, Prieto M, Otley CC.<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8,1],"tags":[],"class_list":["post-25408","post","type-post","status-publish","format-standard","","category-articulos-cientificos","category-generales"],"_links":{"self":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/25408","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/comments?post=25408"}],"version-history":[{"count":0,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/25408\/revisions"}],"wp:attachment":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/media?parent=25408"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/categories?post=25408"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/tags?post=25408"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}